Tibial plateau levelling osteotomy (TPLO) remains the gold standard surgical intervention for dogs with cranial cruciate ligament disease (CCLD). While effective, postoperative recovery and the risk of progressive osteoarthritis (OA) remain significant clinical concerns. A recent study explored the use of allogeneic adipose-derived stem cell (ADSC) enriched secretome as an intra-articular adjunct to TPLO, offering intriguing insights for veterinary surgeons.
Study Overview
- Design: 20 client-owned dogs undergoing TPLO were randomized into two groups:
- Control group (placebo, n=10)
- ADSC-Se group (250 µg intra-articular ADSC-enriched secretome, n=10)
- Follow-up: Clinical and imaging outcomes assessed for 150 days postoperatively.
- Parameters: Lameness, stifle pain, accelerometry, radiography, and ultrasonography.
Key Findings
- Faster Clinical Recovery:
- Median lameness scores improved from 3 → 1 within 15 days in ADSC-Se dogs, compared to 60 days in controls.
- Stifle pain scores decreased from 2 → 0 at 15 days in ADSC-Se, versus 90 days in controls.
- OA Progression:
- Radiographs showed worsening OA in controls (median 1 → 2).
- ADSC-Se dogs demonstrated improvement (median 1 → 0) sustained throughout follow-up.
- Ultrasonography Outcomes:
- Reduced joint effusion (median 1 → 0) from 30 days in ADSC-Se group.
- Cartilage appearance improved from thin → normal, while controls showed deterioration.
- Bone Healing:
- Radiographic bone healing scores were higher in ADSC-Se dogs at 30 days, with mean differences of 1.9 (10-point scale) and 1 (5-point scale).
Mechanistic Insights
The therapeutic effect of ADSC-Se is attributed to paracrine signaling rather than direct regeneration. Secreted products reduce inflammation, inhibit macrophage activation, and lower nitric oxide production in the joint fluid. Importantly, using the whole secretome rather than isolated extracellular vesicles simplifies extraction and reduces costs, enhancing clinical feasibility.
Clinical Implications
- Adjunctive Potential: ADSC-Se may accelerate recovery and mitigate OA progression when combined with TPLO.
- Owner Acceptance: Natural product perception and cost-effectiveness may improve compliance.
- Future Directions: Larger trials are needed to validate safety, optimize dosing, and refine long-term outcomes.
Takeaway for Veterinary Surgeons
This study suggests that ADSC-enriched secretome in canine CCLD could represent a valuable biologic adjunct, and potentially also in other canine orthopedic surgery. It offers a promising step toward integrating regenerative medicine into routine practice by promoting faster recovery and reducing OA progression. These findings encourage further exploration of ADSC-enriched secretome in canine CCLD as part of multimodal management strategies.
